Dai­ichi Sankyo looks to bring FLT3 drug back from the dead with late-stage win in ear­ly AML pa­tients

Dai­ichi Sankyo was on the re­ceiv­ing end of an FDA slap­down more than two years ago for FLT3 drug quizar­tinib and some flim­sy da­ta in acute myeloid leukemia. Look­ing to sal­vage a bad sit­u­a­tion, Dai­ichi is now tout­ing re­sults in ear­li­er AML pa­tients with hopes for a bet­ter out­come with reg­u­la­tors.

Quizar­tinib added to a chemo reg­i­men and then con­tin­ued so­lo sig­nif­i­cant­ly ex­tend­ed the lives of pa­tients with new­ly di­ag­nosed acute myeloid leukemia with the FLT3-ITD mu­ta­tion over chemo alone, ac­cord­ing to topline re­sults from the Phase III QuAN­TUM-FIRST study re­leased Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER